211 related articles for article (PubMed ID: 24804215)
21. Molecular description of evolving paclitaxel resistance in the SKOV-3 human ovarian carcinoma cell line.
Lamendola DE; Duan Z; Yusuf RZ; Seiden MV
Cancer Res; 2003 May; 63(9):2200-5. PubMed ID: 12727840
[TBL] [Abstract][Full Text] [Related]
22. Differential gene expression analysis related to extracellular matrix components in drug-resistant RPMI-8226 cell line.
Mutlu P; Ural AU; Gündüz U
Biomed Pharmacother; 2012 Apr; 66(3):228-31. PubMed ID: 22425183
[TBL] [Abstract][Full Text] [Related]
23. MiR-130a and MiR-374a Function as Novel Regulators of Cisplatin Resistance in Human Ovarian Cancer A2780 Cells.
Li N; Yang L; Wang H; Yi T; Jia X; Chen C; Xu P
PLoS One; 2015; 10(6):e0128886. PubMed ID: 26043084
[TBL] [Abstract][Full Text] [Related]
24. Improvement of sensitivity to platinum compound with siRNA knockdown of upregulated genes in platinum complex-resistant ovarian cancer cells in vitro.
Yanagie H; Hisa T; Ogata A; Miyazaki A; Nonaka Y; Nishihira T; Osada I; Sairennji T; Sugiyama H; Furuya Y; Kidani Y; Takamoto S; Takahashi H; Eriguchi M
Biomed Pharmacother; 2009 Sep; 63(8):553-60. PubMed ID: 18571892
[TBL] [Abstract][Full Text] [Related]
25. Inhibitor of apoptosis proteins (IAPs) mediate collagen type XI alpha 1-driven cisplatin resistance in ovarian cancer.
Rada M; Nallanthighal S; Cha J; Ryan K; Sage J; Eldred C; Ullo M; Orsulic S; Cheon DJ
Oncogene; 2018 Aug; 37(35):4809-4820. PubMed ID: 29769618
[TBL] [Abstract][Full Text] [Related]
26. miR-509-3p enhances platinum drug sensitivity in ovarian cancer.
Niu L; Ni H; Hou Y; Du Q; Li H
Gene; 2019 Feb; 686():63-67. PubMed ID: 30408550
[TBL] [Abstract][Full Text] [Related]
27. TGFBI promoter hypermethylation correlating with paclitaxel chemoresistance in ovarian cancer.
Wang N; Zhang H; Yao Q; Wang Y; Dai S; Yang X
J Exp Clin Cancer Res; 2012 Jan; 31(1):6. PubMed ID: 22248469
[TBL] [Abstract][Full Text] [Related]
28. Analysis of MDR genes expression and cross-resistance in eight drug resistant ovarian cancer cell lines.
Januchowski R; Sterzyńska K; Zaorska K; Sosińska P; Klejewski A; Brązert M; Nowicki M; Zabel M
J Ovarian Res; 2016 Oct; 9(1):65. PubMed ID: 27756418
[TBL] [Abstract][Full Text] [Related]
29. Two different docetaxel resistant MCF-7 sublines exhibited different gene expression pattern.
Işeri OD; Kars MD; Gündüz U
Mol Biol Rep; 2012 Apr; 39(4):3505-16. PubMed ID: 21720762
[TBL] [Abstract][Full Text] [Related]
30. Cross‑validation of genes potentially associated with neoadjuvant chemotherapy and platinum‑based chemoresistance in epithelial ovarian carcinoma.
Zhang K; Wang W; Chen L; Liu Y; Hu J; Guo F; Tian W; Wang Y; Xue F
Oncol Rep; 2020 Sep; 44(3):909-926. PubMed ID: 32705213
[TBL] [Abstract][Full Text] [Related]
31. Profiling of proteins associated with cisplatin resistance in ovarian cancer cells.
Zhu K; Fukasawa I; Fujinoki M; Furuno M; Inaba F; Yamazaki T; Kamemori T; Kousaka N; Ota Y; Hayashi M; Maehama T; Inaba N
Int J Gynecol Cancer; 2005; 15(5):747-54. PubMed ID: 16174219
[TBL] [Abstract][Full Text] [Related]
32. MicroRNA-873 mediates multidrug resistance in ovarian cancer cells by targeting ABCB1.
Wu DD; Li XS; Meng XN; Yan J; Zong ZH
Tumour Biol; 2016 Aug; 37(8):10499-506. PubMed ID: 26850595
[TBL] [Abstract][Full Text] [Related]
33. Drug resistance evaluation in novel 3D in vitro model.
Nowacka M; Sterzynska K; Andrzejewska M; Nowicki M; Januchowski R
Biomed Pharmacother; 2021 Jun; 138():111536. PubMed ID: 34311534
[TBL] [Abstract][Full Text] [Related]
34. Oridonin effectively reverses cisplatin drug resistance in human ovarian cancer cells via induction of cell apoptosis and inhibition of matrix metalloproteinase expression.
Ma S; Tan W; Du B; Liu W; Li W; Che D; Zhang G
Mol Med Rep; 2016 Apr; 13(4):3342-8. PubMed ID: 26935490
[TBL] [Abstract][Full Text] [Related]
35. New and Old Genes Associated with Primary and Established Responses to Paclitaxel Treatment in Ovarian Cancer Cell Lines.
Świerczewska M; Klejewski A; Brązert M; Kaźmierczak D; Iżycki D; Nowicki M; Zabel M; Januchowski R
Molecules; 2018 Apr; 23(4):. PubMed ID: 29649113
[TBL] [Abstract][Full Text] [Related]
36. The TGFBI gene and protein expression in topotecan resistant ovarian cancer cell lines.
Wojtowicz K; Świerczewska M; Nowicki M; Januchowski R
Adv Med Sci; 2023 Sep; 68(2):379-385. PubMed ID: 37806183
[TBL] [Abstract][Full Text] [Related]
37. Demonstration of differential gene expression between sensitive and resistant ovarian tumor cells by fluorescence differential display-PCR analysis.
Li L; Luan Y; Li X; Tang B; Zhang W; Li D; Zhao J; Wang G; Ding H; Reed E; Li QQ
Oncol Rep; 2005 May; 13(5):793-9. PubMed ID: 15809740
[TBL] [Abstract][Full Text] [Related]
38. MiR-27a modulates MDR1/P-glycoprotein expression by targeting HIPK2 in human ovarian cancer cells.
Li Z; Hu S; Wang J; Cai J; Xiao L; Yu L; Wang Z
Gynecol Oncol; 2010 Oct; 119(1):125-30. PubMed ID: 20624637
[TBL] [Abstract][Full Text] [Related]
39. Mechanistic analysis of taxol-induced multidrug resistance in an ovarian cancer cell line.
Wang NN; Zhao LJ; Wu LN; He MF; Qu JW; Zhao YB; Zhao WZ; Li JS; Wang JH
Asian Pac J Cancer Prev; 2013; 14(9):4983-8. PubMed ID: 24175763
[TBL] [Abstract][Full Text] [Related]
40. Identifying novel hypoxia-associated markers of chemoresistance in ovarian cancer.
McEvoy LM; O'Toole SA; Spillane CD; Martin CM; Gallagher MF; Stordal B; Blackshields G; Sheils O; O'Leary JJ
BMC Cancer; 2015 Jul; 15():547. PubMed ID: 26205780
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
